Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.

@article{Garca2005PriorET,
  title={Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.},
  author={Jorge A. Garc{\'i}a and Vivian A. Weinberg and Eric Jay Small},
  journal={Clinical prostate cancer},
  year={2005},
  volume={4 2},
  pages={113-7}
}
BACKGROUND Hormone-refractory prostate cancer (HRPC) has modest response rates to second-line estrogenic agents such as diethylstilbestrol and the herbal product PC SPES. Estramustine phosphate (EMP) is a microtubule inhibitory agent with estrogenic properties commonly used in patients with metastatic HRPC. To determine whether previous response to second-line estrogen therapy would predict subsequent response to EMP-based chemotherapy, a retrospective study was conducted. PATIENTS AND… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…